| Title |
|
|
|
Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing
| |
| Author |
|
|
|
| |
| Abstract |
|
|
|
| Genetic engineering of T cells with tumor specific T-cell receptors (TCR) is a promising strategy to redirect their specificity against cancer cells in adoptive T cell therapy protocols. Most studies are exploiting integrating retro- or lentiviral vectors to permanently introduce the therapeutic TCR, which can pose serious safety issues when treatment-related toxicities would occur. Therefore, we developed a versatile, non genotoxic transfection method for human unstimulated CD8+ T cells. We describe an optimized double sequential electroporation platform whereby Dicer substrate small interfering RNAs (DsiRNA) are first introduced to suppress endogenous TCR α and β expression, followed by electroporation with DsiRNA-resistant tumor-specific TCR mRNA. We demonstrate that sequential double electroporation of human primary unstimulated T cells with DsiRNA and TCR mRNA leads to unprecedented levels of transgene TCR expression due to a strongly reduced degree of TCR mispairing. Importantly, superior transgenic TCR expression boosts epitope-specific CD8+ T cell activation and killing activity. Altogether, DsiRNA and TCR mRNA sequential double electroporation is a rapid, non integrating and highly efficient approach with an enhanced biosafety profile to engineer T cells with antigen-specific TCRs for use in early phase clinical trials. |
| |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
Frontiers in immunology. - Place of publication unknown | |
| Publication |
|
|
|
Place of publication unknown : 2018
| |
| ISSN |
|
|
|
1664-3224
| |
| Volume/pages |
|
|
|
9(2018), 14 p.
| |
| Article Reference |
|
|
|
2503
| |
| ISI |
|
|
|
000449420000001
| |
| Pubmed ID |
|
|
|
30464762
| |
| Medium |
|
|
|
E-only publicatie
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (open access) |
|
|
| | |
|